On July 23, 2024 ICE Bioscience reported that the company has successfully closed its B++ round of financing (Press release, ICE Bioscience, JUL 23, 2024, View Source;catname=icenews [SID1234647428]). This achievement marks another substantial endorsement from the capital markets, following our significant fundraising effort in August 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a high-growth CRO, this new funding will enable us to expand our cutting-edge services to the global pharmaceutical industry, enhancing our ability to support our clients in drug discovery and development.

We are grateful for the trust and commitment from our financial partners as we continue to innovate and grow. Stay tuned for more updates as we further our mission to drive progress and support the pharmaceutical sector.